Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate given via standard versus accelerated vaccination schedules: a phase 1, single-center, double-blind, sequential-group, randomized, placebo-controlled clinical trial

Bibliographische Detailangaben

Veröffentlicht in:	The Lancet infectious diseases 2020-05, Vol.20 (9), p.1061-1070
Hauptverfasser:	Stephenson, Kathryn E., Tan, C. Sabrina, Walsh, Stephen R., Hale, Andrew, Ansel, Jessica L., Kanjilal, Diane G., Jaegle, Kate, Peter, Lauren, Borducchi, Erica N., Nkolola, Joseph, Makoni, Tatenda, Fogel, Rachel, Bradshaw, Connor, Tyler, Anna, Moseley, Edward, Chandrashekar, Abishek, Yanosick, Katherine E., Seaman, Michael S., Eckels, Kenneth H., De La Barrera, Rafael A., Thompson, Jason, Dawson, Peter, Thomas, Stephen J., Michael, Nelson L., Modjarrad, Kayvon, Barouch, Dan H.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!